Thrombolysis in fulminant purpura: observations on changes in microcirculatory perfusion during successful treatment.
Spronk
Peter E
PE
Department of Intensive Care Medicine, Gelre Hospitals, Lukas site, Alpeldoorn, The Netherlands. p.spronk@gelre.nl
Rommes
Johannes H
JH
Schaar
Cees
C
Ince
Can
C
D004423:Ear; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy* / Q000209:etiology; D007650:Ketanserin / Q000627:therapeutic use; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use; D011018:Pneumonia, Pneumococcal / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use; D012039:Regional Blood Flow; D018805:Sepsis / Q000150:complications; D012867:Skin / Q000098:blood supply* / Q000187:drug effects; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D007650:Ketanserin; D010959:Tissue Plasminogen Activator; D005996:Nitroglycerin